Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06432660 · ClinicalTrials.gov registry record
Eye Plaque Brachytherapy for Ocular Melanoma
A clinical trial of Ocular Melanoma, sponsored by Duke University.
- Active
- Registry status
- 42
- Enrollment target
- 1
- Study location
NCT06432660: Active study of Ocular Melanoma, sponsored by Duke University.
NCT06432660 is a study of Ocular Melanoma that is active but no longer recruiting, run by Duke University. The registered enrollment target is 42 participants, below the 49-participant average among 4 other Ocular Melanoma trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06432660, a study of Ocular Melanoma, is active but no longer recruiting, sponsored by Duke University.
- ACTIVE NOT RECRUITING
- Registry status
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This prospective registry study will evaluate doses utilized in eye plaque brachytherapy for the treatment of ocular melanoma and their associated outcomes. The goal of this study is to evaluate if lower doses of radiation can maintain high local control rates while minimizing the toxicities related to radiation therapy.
Primary Outcome
Number of disease free participants expressed as a percentage of the total number of participants enrolled
Conditions Studied
Interventions
- OTHER Data collection
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2024-07-03 |
| Est. Completion | 2029-09 |
What the registry record for NCT06432660 still lists
NCT06432660 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 49-participant average among 4 other Ocular Melanoma trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Ocular Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Data collection is the first listed.
NCT06432660 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06432660 about?
NCT06432660 is a clinical study titled "Eye Plaque Brachytherapy for Ocular Melanoma". This prospective registry study will evaluate doses utilized in eye plaque brachytherapy for the treatment of ocular melanoma and their associated outcomes. The goal of this study is to evaluate if lower doses of radiation can maintain high local control rates while minimizing the toxicities related...
What is the current status of trial NCT06432660?
This trial is currently active not recruiting. The enrollment target is 42 participants. The study started on 2024-07-03. Estimated completion is 2029-09.
What conditions does trial NCT06432660 study?
This clinical trial studies the following conditions: Ocular Melanoma.
What interventions are being tested in trial NCT06432660?
The interventions under investigation include: Data collection (OTHER).
Who is sponsoring clinical trial NCT06432660?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06432660 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
RECRUITING · Phase 1
-
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
RECRUITING · Phase 2
-
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
RECRUITING · Phase 3
-
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI